Navidea Biopharmaceuticals, Inc. – ‘10-K’ for 12/31/20 – ‘EX-21.1’

On:  Friday, 3/26/21, at 5:01pm ET   ·   For:  12/31/20   ·   Accession #:  1437749-21-7329   ·   File #:  1-35076

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.23M 
 2: EX-21.1     Subsidiaries List                                   HTML     26K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     25K 
 4: EX-24.1     Power of Attorney                                   HTML     30K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
13: R1          Document And Entity Information                     HTML     64K 
14: R2          Consolidated Balance Sheets                         HTML    135K 
15: R3          Consolidated Balance Sheets (Parentheticals)        HTML     46K 
16: R4          Consolidated Statements of Operations               HTML    115K 
17: R5          Consolidated Statements of Comprehensive Loss       HTML     38K 
18: R6          Consolidated Statements of Stockholders' Equity     HTML    194K 
                (Deficit)                                                        
19: R7          Consolidated Statements of Stockholders' Equity     HTML     26K 
                (Deficit) (Parentheticals)                                       
20: R8          Consolidated Statements of Cash Flows               HTML    112K 
21: R9          Note 1 - Organization and Summary of Significant    HTML     99K 
                Accounting Policies                                              
22: R10         Note 2 - Liquidity                                  HTML     50K 
23: R11         Note 3 - Revenue From Contracts With Customers      HTML     73K 
24: R12         Note 4 - Stock-based Compensation                   HTML     60K 
25: R13         Note 5 - Loss Per Share                             HTML     31K 
26: R14         Note 6 - Stock Subscriptions and Other Receivables  HTML     38K 
                and Concentrations of Credit Risk                                
27: R15         Note 7 - Inventory                                  HTML     32K 
28: R16         Note 8 - Property and Equipment                     HTML     43K 
29: R17         Note 9 - Investment in Macrophage Therapeutics,     HTML     53K 
                Inc.                                                             
30: R18         Note 10 - Accounts Payable, Accrued Liabilities     HTML     36K 
                and Other                                                        
31: R19         Note 11 - Notes Payable                             HTML     37K 
32: R20         Note 12 - Leases                                    HTML     60K 
33: R21         Note 13 - Commitments and Contingencies             HTML     66K 
34: R22         Note 14 - Equity Instruments                        HTML     72K 
35: R23         Note 15 - Income Taxes                              HTML    119K 
36: R24         Note 16 - Segments                                  HTML    120K 
37: R25         Note 17 - Material Agreements                       HTML     36K 
38: R26         Note 18 - Employee Benefit Plan                     HTML     29K 
39: R27         Note 19 - Supplemental Disclosure for Statements    HTML     33K 
                of Cash Flows                                                    
40: R28         Note 20 - Subsequent Events                         HTML     33K 
41: R29         Significant Accounting Policies (Policies)          HTML    167K 
42: R30         Note 1 - Organization and Summary of Significant    HTML     40K 
                Accounting Policies (Tables)                                     
43: R31         Note 3 - Revenue From Contracts With Customers      HTML     50K 
                (Tables)                                                         
44: R32         Note 4 - Stock-based Compensation (Tables)          HTML     57K 
45: R33         Note 6 - Stock Subscriptions and Other Receivables  HTML     35K 
                and Concentrations of Credit Risk (Tables)                       
46: R34         Note 7 - Inventory (Tables)                         HTML     31K 
47: R35         Note 8 - Property and Equipment (Tables)            HTML     40K 
48: R36         Note 10 - Accounts Payable, Accrued Liabilities     HTML     33K 
                and Other (Tables)                                               
49: R37         Note 12 - Leases (Tables)                           HTML     61K 
50: R38         Note 14 - Equity Instruments (Tables)               HTML     39K 
51: R39         Note 15 - Income Taxes (Tables)                     HTML    108K 
52: R40         Note 16 - Segments (Tables)                         HTML    110K 
53: R41         Note 1 - Organization and Summary of Significant    HTML     97K 
                Accounting Policies (Details Textual)                            
54: R42         Note 1 - Organization and Summary of Significant    HTML     50K 
                Accounting Policies - Assumptions Used to                        
                Calculate Fair Value of Stock Option Awards                      
                Granted (Details)                                                
55: R43         Note 2 - Liquidity (Details Textual)                HTML    163K 
56: R44         Note 3 - Revenue From Contracts With Customers      HTML     50K 
                (Details Textual)                                                
57: R45         Note 3 - Revenue From Contracts With Customers -    HTML     42K 
                Disaggregation of Revenue (Details)                              
58: R46         Note 3 - Revenue From Contracts With Customers -    HTML     33K 
                Changes in Contract Liabilities (Details)                        
59: R47         Note 4 - Stock-based Compensation (Details          HTML     52K 
                Textual)                                                         
60: R48         Note 4 - Stock-based Compensation - Summary of      HTML     57K 
                Stock Option Activity (Details)                                  
61: R49         Note 4 - Stock-based Compensation - Summary of      HTML     41K 
                Unvested Restricted Stock (Details)                              
62: R50         Note 5 - Loss Per Share (Details Textual)           HTML     30K 
63: R51         Note 6 - Stock Subscriptions and Other Receivables  HTML     33K 
                and Concentrations of Credit Risk (Details                       
                Textual)                                                         
64: R52         Note 6 - Stock Subscriptions and Other Receivables  HTML     33K 
                and Concentrations of Credit Risk - Accounts and                 
                Other Receivables (Details)                                      
65: R53         Note 7 - Inventory (Details Textual)                HTML     31K 
66: R54         Note 7 - Inventory - Net Inventory (Details)        HTML     30K 
67: R55         Note 8 - Property and Equipment (Details Textual)   HTML     26K 
68: R56         Note 8 - Property and Equipment - Summary of Major  HTML     45K 
                Classes of Property and Equipment (Details)                      
69: R57         Note 9 - Investment in Macrophage Therapeutics,     HTML    106K 
                Inc. (Details Textual)                                           
70: R58         Note 10 - Accounts Payable, Accrued Liabilities     HTML     31K 
                and Other (Details Textual)                                      
71: R59         Note 10 - Accounts Payable, Accrued Liabilities     HTML     32K 
                and Other - Accrued Liabilities and Other                        
                (Details)                                                        
72: R60         Note 11 - Notes Payable (Details Textual)           HTML     57K 
73: R61         Note 12 - Leases (Details Textual)                  HTML     51K 
74: R62         Note 12 - Leases - Impact of the Adoption of ASU    HTML     39K 
                2016-02 on Our Balance Sheet (Details)                           
75: R63         Note 12 - Leases - Maturity of Lease Liabilities    HTML     39K 
                (Details)                                                        
76: R64         Note 12 - Leases - Balance Sheet Classification     HTML     34K 
                (Details)                                                        
77: R65         Note 12 - Leases - Other Information (Details)      HTML     28K 
78: R66         Note 13 - Commitments and Contingencies (Details    HTML     98K 
                Textual)                                                         
79: R67         Note 14 - Equity Instruments (Details Textual)      HTML    282K 
80: R68         Note 14 - Equity Instruments - Outstanding          HTML     42K 
                Warrants (Details)                                               
81: R69         Note 15 - Income Taxes (Details Textual)            HTML     55K 
82: R70         Note 15 - Income Taxes - Components of Deferred     HTML     47K 
                Tax Assets (Details)                                             
83: R71         Note 15 - Income Taxes - Net Operating Loss and     HTML     97K 
                Credit Carryforwards (Details)                                   
84: R72         Note 15 - Income Taxes - Reconciliations Between    HTML     47K 
                the Statutory Federal Income Tax Rate and the                    
                Effective Tax Rate (Details)                                     
85: R73         Note 16 - Segments (Details Textual)                HTML     38K 
86: R74         Note 16 - Segments - Segment Information (Details)  HTML    119K 
87: R75         Note 17 - Material Agreements (Details Textual)     HTML     56K 
88: R76         Note 18 - Employee Benefit Plan (Details Textual)   HTML     25K 
89: R77         Note 19 - Supplemental Disclosure for Statements    HTML     83K 
                of Cash Flows (Details Textual)                                  
90: R78         Note 20 - Subsequent Events (Details Textual)       HTML     64K 
92: XML         IDEA XML File -- Filing Summary                      XML    175K 
91: EXCEL       IDEA Workbook of Financial Reports                  XLSX    110K 
 7: EX-101.INS  XBRL Instance -- navb-20201231                       XML   2.61M 
 9: EX-101.CAL  XBRL Calculations -- navb-20201231_cal               XML    147K 
10: EX-101.DEF  XBRL Definitions -- navb-20201231_def                XML   2.12M 
11: EX-101.LAB  XBRL Labels -- navb-20201231_lab                     XML   1.44M 
12: EX-101.PRE  XBRL Presentations -- navb-20201231_pre              XML   2.09M 
 8: EX-101.SCH  XBRL Schema -- navb-20201231                         XSD    271K 
93: ZIP         XBRL Zipped Folder -- 0001437749-21-007329-xbrl      Zip    254K 

‘EX-21.1’   —   Subsidiaries List

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/14/22  Navidea Biopharmaceuticals, Inc.  S-1         2/11/22    3:944K                                   RDG Filings/FA
 5/24/21  Navidea Biopharmaceuticals, Inc.  424B3                  1:190K                                   RDG Filings/FA
 5/13/21  Navidea Biopharmaceuticals, Inc.  S-1                    3:378K                                   RDG Filings/FA

33 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/21  Navidea Biopharmaceuticals, Inc.  8-K:1,3,5,9 3/02/21    5:363K                                   RDG Filings/FA
 2/08/21  Navidea Biopharmaceuticals, Inc.  S-3                    4:908K                                   RDG Filings/FA
11/13/20  Navidea Biopharmaceuticals, Inc.  S-8        11/13/20    4:1.7M                                   RDG Filings/FA
 9/02/20  Navidea Biopharmaceuticals, Inc.  8-K:1,5,9   8/28/20    6:435K                                   RDG Filings/FA
 8/25/20  Navidea Biopharmaceuticals, Inc.  S-3                    4:401K                                   RDG Filings/FA
 8/14/20  Navidea Biopharmaceuticals, Inc.  10-Q        6/30/20   65:6.4M                                   RDG Filings/FA
 7/31/20  Navidea Biopharmaceuticals, Inc.  8-K:5,9     7/27/20    2:123K                                   RDG Filings/FA
 5/12/20  Navidea Biopharmaceuticals, Inc.  8-K:1,3,5,9 5/06/20    5:347K                                   RDG Filings/FA
 3/18/20  Navidea Biopharmaceuticals, Inc.  10-K       12/31/19   97:10M                                    RDG Filings/FA
12/31/19  Navidea Biopharmaceuticals, Inc.  S-3                    4:979K                                   RDG Filings/FA
12/11/19  Navidea Biopharmaceuticals, Inc.  8-K:1,3,9  12/06/19    4:270K                                   RDG Filings/FA
 6/17/19  Navidea Biopharmaceuticals, Inc.  8-K:1,3,8,9 6/13/19    7:521K                                   RDG Filings/FA
 4/26/19  Navidea Biopharmaceuticals, Inc.  8-K:3,5,9   4/26/19    2:30K                                    RDG Filings/FA
11/09/18  Navidea Biopharmaceuticals, Inc.  10-Q        9/30/18   72:7.1M                                   RDG Filings/FA
10/05/18  Navidea Biopharmaceuticals, Inc.  8-K:5,9    10/01/18    2:95K                                    RDG Filings/FA
 5/09/18  Navidea Biopharmaceuticals, Inc.  10-Q        3/31/18   74:6M                                     RDG Filings/FA
 3/31/17  Navidea Biopharmaceuticals, Inc.  10-K       12/31/16   96:7.9M                                   Blueprint/FA
 3/09/17  Navidea Biopharmaceuticals, Inc.  8-K:1,2,3,9 3/03/17    6:575K                                   Toppan Merrill/FA
11/30/16  Navidea Biopharmaceuticals, Inc.  8-K:1,9    11/23/16    3:857K                                   Toppan Merrill/FA
 5/10/16  Navidea Biopharmaceuticals, Inc.  8-K:5,9     5/04/16    2:60K                                    Toppan Merrill/FA
 1/11/16  Navidea Biopharmaceuticals, Inc.  8-K:1,8,9   1/06/16    4:271K                                   Toppan Merrill/FA
10/09/15  Navidea Biopharmaceuticals, Inc.  8-K/A:9     5/11/15    2:673K                                   Toppan Merrill/FA
 8/26/15  Navidea Biopharmaceuticals, Inc.  8-K:1,8,9   8/20/15    4:233K                                   Toppan Merrill/FA
 5/15/15  Navidea Biopharmaceuticals, Inc.  8-K:1,2,8,9 5/11/15    7:562K                                   Toppan Merrill/FA
 5/11/15  Navidea Biopharmaceuticals, Inc.  10-Q        3/31/15   66:5M
11/10/14  Navidea Biopharmaceuticals, Inc.  10-Q        9/30/14   60:4.3M
 8/11/14  Navidea Biopharmaceuticals, Inc.  10-Q        6/30/14   62:4.5M
 3/07/14  Navidea Biopharmaceuticals, Inc.  8-K:1,2,3,7 3/04/14    9:858K                                   Toppan Merrill/FA
11/12/13  Navidea Biopharmaceuticals, Inc.  10-Q        9/30/13   54:4.4M                                   Workiva Inc.
 9/05/13  Navidea Biopharmaceuticals, Inc.  8-K:1,8,9   8/29/13    3:459K                                   Toppan Merrill/FA
 6/28/13  Navidea Biopharmaceuticals, Inc.  8-K/A:1,2,3 6/24/13    8:1M                                     Toppan Merrill/FA
 6/26/13  Navidea Biopharmaceuticals, Inc.  8-K:1,2,3,5 6/24/13    4:177K                                   Toppan Merrill/FA
 4/11/12  Navidea Biopharmaceuticals, Inc.  8-K/A:1,5,812/09/11    2:476K                                   Toppan Merrill/FA